ISPOR Europe 2026
Panel Access and Pricing track
Could a Higher Willingness-to-Pay for 'Innovative' Therapies in Cost Effectiveness HTAs Help Enable Europe to Retain R&D and Manufacturing?
Tue, Nov 10, 2026 · 4:45–5:45 PM CET Hall D, Level -2, Austria Center Vienna
About this session
Issue • It takes increasingly innovative approaches to deliver further health gains for many therapy areas, but such approaches are inherently higher risk for manufacturers. • New pharmacological modalities benefits may go beyond the QALY so how can this be captured? How can this be fairly and transparently reflected in decision making?
